Global
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Spain
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Spanish operations at oncopeptides.es
Austria
Italy
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Italian operations at oncopeptides.it
Change Language
Global
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Spain
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Spanish operations at oncopeptides.es
Austria
Italy
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Italian operations at oncopeptides.it
Change Language
Redeye analyst Richard Remanius recently interviewed CEO Sofia Heigis about Q4 and the upcoming new share issue of approximately SEK 200 million. The interview is held in Swedish.
Watch the interview via this link (requires free membership at Redeye).
